OJI  Vol.3 No.3 , September 2013
Roles of antigen receptors and CA215 in the innate immunity of cancer cells
Abstract: Antigen receptors, including immunoglobulins and T-cell receptors, are known to be widely expressed by cancer cells through unconfirmed mechanisms and for unknown purposes. Recently, a monoclonal antibody, designated as RP215, was generated against the ovarian cancer cell line, OC-3-VGH, and was shown to react with CA215, which consisted mainly of these cancer cell-expressed antigen receptors. Experimental evidence has clearly indicated that cancerous immunoglobulins play significant roles in the growth and proliferation of cancer cells in vitro and in vivo. RP215 and anti-antigen receptor antibodies were equally effective in inducing apoptosis and complement-dependent cytotoxicity reactions to cultured cancer cells. Through gene regulation studies, both RP215 and antibodies against antigen-receptors were shown to affect more than a dozen of genes involved in cell proliferation (such as NFκB-1, IgG, P21, cyclin D1, ribosomal P1, and c-fos). Furthermore, selected toll-like receptor genes (TLR- 2, -3, -4, and -9) were also found to be highly regulated by both RP215 and anti-antigen receptor antibodies. For example, RP215 and anti-antigen receptor antibodies were found to both up-regulate TLR-2 and/or TLR-3 and down- regulate TLR-4 and TLR-9 intwo types of cancer cells. Based on these studies, it is reasonable to postulate that cancerous immunoglobulins play important roles in the modulation of the innate immune system to allow the growth and survival of cancer cells within the human body. Consequently, RP215 inits humanized forms may be utilized to target cancer cells for potential therapeutic purposes.
Cite this paper: Lee, G. and Liu, S. (2013) Roles of antigen receptors and CA215 in the innate immunity of cancer cells. Open Journal of Immunology, 3, 127-138. doi: 10.4236/oji.2013.33018.

[1]   Kimoto, Y. (1998) Expression of heavy-chain constant region of immunoglobulin and T-cell receptor gene transcripts in human non-hematopoietic tumor cell lines. Genes, Chromosomes and Cancer, 22, 83-86. doi:10.1002/(SICI)1098-2264(1998)22:1<83::AID-GCC12>3.0.CO;2-O

[2]   Li, J., Tan, C., Xiang, Q., Zhang, X., Ma, J., Wang, J.-R., et al. (2001) Proteomic detection of changes in protein synthesis induced by NGX6 transfected in human nasopharyngeal carcinoma cells. Journal of Protein Chemistry, 20, 265-271. doi:10.1023/A:1010912311564

[3]   Qiu, X., Zhu, X., Zhang, L., Mao, Y., Zhang, J., Hao, P., et al. (2003) Human epithelial cancers secrete immunoglobulin G with unidentified specificity to promote growth and survival of tumor cells. Cancer Research, 63, 6488- 6495.

[4]   Li, M., Feng, D.-Y., Ren, W., Zheng, L., Zheng, H., Tang, M., et al. (2004) Expression of immunoglobulin kappa light chain constant region in abnormal human cervical epithelial cells. International Journal of Biochemistry and Cell Biology, 36, 2250-2257. doi:10.1016/j.biocel.2004.03.017

[5]   Babbage, G., Ottensmeier, C., Blaydes, J., Stevenson, F., and Sahota, S. (2006) Immunoglobulin heavy chain locus events and expression of activation-induced cytidine deaminase in epithelial breast cancer cell lines. Cancer Research, 66, 3996-4000. doi:10.1158/0008-5472.CAN-05-3704

[6]   Chen, Z. and Gu, J. (2007) Immunoglobulin G expression in carcinomas and cancer cell lines. FASEB Journal, 21, 2931-2938. doi:10.1096/fj.07-8073com

[7]   Zheng, H., Li, M., Liu, H., Ren, W., Hu, D.-S., Shi, Y., et al. (2007) Immunoglobulin alpha heavy chain derived from human epithelial cancer cells promotes the access of S phase and growth of cancer cells. Cell Biology International, 31, 82-87. doi:10.1016/j.cellbi.2006.09.009

[8]   Zheng, H., Li, M., Ren, W., Zeng, L., Liu, H.-D., Hu, D., et al. (2007) Expression and secretion of immunoglobulin alpha heavy chain with diverse VDJ recombinations by human epithelial cancer cells. Molecular Immunology, 44, 2221-2227. doi:10.1016/j.molimm.2006.11.010

[9]   Huang, J., Sun, X., Mao, Y., Zhu, X., Zhang, P., Zhang, L., et al. (2008) Expression of immunoglobulin gene with classical V-(D)-J rearrangement in mouse brain neurons. International Journal of Biochemistry and Cell Biology, 40, 1604-1615. doi:10.1016/j.biocel.2007.12.004

[10]   Lee, G., Laflamme, E., Chien, C.-H. and Ting, H.H. (2008) Molecular identity of a pan cancer marker, CA215. Cancer Biology and Therapy, 7, 2007-2014. doi:10.4161/cbt.7.12.6984

[11]   Zhu, X., Li, C., Sun, X., Mao, Y., Li, G., Liu, X., et al. (2008) Immunoglobulin mRNA and protein expression in human oral epithelial tumor cells. Applied Immunohistochemistry & Molecular Morphology, 16, 232-238. doi:10.1097/PAI.0b013e31814c915a

[12]   Huang, J., Zhang, L., Ma, T., Zhang, P. and Qiu, X. (2009) Expression of immunoglobulin gene with classical V-(D)- J rearrangement in mouse testis and epididymis. Journal of Histochemistry and Cytochemistry, 57, 339-349. doi:10.1369/jhc.2008.951434

[13]   Lee, G. and Ge, B. (2009) Cancer cell expressions of immunoglobulin heavy chains with unique carbohydrate-associated biomarker. Cancer Biomarkers, 5, 177-188.

[14]   Zheng, J., Huang, J., Mao, Y., Liu, S., Sun, X., Zhu, X., et al. (2009) Immunoglobulin gene transcripts have distinct VHDJH recombination characteristics in human epithelial cancer cells. Journal of Biological Chemistry, 284, 13610- 13619. doi:10.1074/jbc.M809524200

[15]   Zhang, S., Mao, Y., Huang, J., Ma, T., Zhang, L., Zhu, X., et al. (2010) Immunoglobulin gene locus events in epithelial cells of lactating mouse mammary glands. Cellular and Molecular Life Sciences, 67, 985-994. doi:10.1007/s00018-009-0231-z

[16]   Hu, D., Duan, Z., Li, M., Jiang, Y., Liu, H., Zheng, H., et al. (2011) Heterogeneity of aberrant immunoglobulin expression in cancer cells. Cellular and Molecular Immunology, 8, 479-485. doi:10.1038/cmi.2011.25

[17]   Zhang, L., Hu, S., Korteweg, C., Chen, Z., Qiu, Y., Su, M., et al. (2012) Expression of immunoglobulin G in esophageal squamous cell carcinomas and its association with tumor grade and Ki67. Human Pathology, 43, 423- 434. doi:10.1016/j.humpath.2011.05.020

[18]   Hu, F., Zhang, L., Zheng, J., Zhao, L., Huang, J., Shao, W., et al. (2012) Spontaneous production of immunoglobulin M in human epithelial cancer cells. PLoS ONE, 7, e51423. doi:10.1371/journal.pone.0051423

[19]   Li, M., Zheng, H., Duan, Z., Liu, H., Hu, D., Bode, A., et al. (2012) Promotion of cell proliferation and inhibition of ADCC by cancerous immunoglobulin expressed in cancer cell lines. Cellular & Molecular Immunology, 9, 54-61. doi:10.1038/cmi.2011.40

[20]   Lee, C.Y., Chen, K.W., Sheu, F.S., Tsang, A., Chao, K.C., and Ng, H.T. (1992) Studies of a tumor-associated antigen, COX-1, recognized by a monoclonal antibody. Cancer Immunology, Immunotherapy, 35, 19-26. doi:10.1007/BF01741050

[21]   Lee, G., Wu, Q., Li, C. H., Ting, H.H. and Chien, C.-H. (2006) Recent studies of a new carbohydrate-associated pan cancer marker, CA215. Journal of Clinical Ligand Assay, 29, 47-51. doi:10.4161/cbt.7.12.6984

[22]   Lee, G., Zhu, M., Ge, B. and Potzold, S. (2012) Widespread expressions of immunoglobulin superfamily proteins in cancer cells. Cancer Immunology, Immunotherapy, 61, 89-99. doi:10.1007/s00262-011-1088-1

[23]   Lee, G. and Azadi P. (2012) Peptide mapping and glycoanalysis of cancer cell-expressed glycoproteins CA215 recognized by RP215 monoclonal antibody. Journal of Carbohydrate Chemistry, 31, 10-30. doi:10.1080/07328303.2011.626544

[24]   Lee, G., Ge, B., Huang, T.-K., Zheng, G., Duan, J. and Wang, I.H.Y. (2009) Positive identification of CA215 pan cancer biomarker from serum specimens of cancer patients. Cancer Biomarkers, 6, 111-117.

[25]   Lee, G., Zhu, M., Ge, B., Cheung, A. P., Chien, C.-H., Chow, S.-N., et al. (2012) Carbohydrate-associated immunodominant epitope(s) of CA215. Immunological Investigations, 41, 317-336. doi:10.3109/08820139.2011.633141

[26]   Qiu, X., Liu, W. and Lee, G. (2013) The application of RP215 monoclonal antibody in the study of proliferation, migration, chemo-resistance, of cancer cells as well as cancer stem cells. Chinese Patent No. 201110211923.8.

[27]   Lee, G., Cheung, A., Ge, B., Zhu, M., Giolma, B., Li, B., et al. (2012) CA215 and GnRH receptor as targets for cancer therapy. Cancer Immunology, Immunotherapy, 1- 13. doi:10.1007/s00262-012-1230-8

[28]   Tang, Y., Zhang, H. and Lee, G. (2013) Similar gene regulation patterns for growth inhibition of cancer cells by RP215 or anti-antigen receptors. Journal of Cancer Science and Therapy, 5, 200-208. doi:10.4172/1948-5956.1000207

[29]   So, E.Y. and Ouchi, T. (2010) The application of toll like receptors for cancer therapy. International Journal of Biological Sciences, 6, 675-681. doi:10.7150/ijbs.6.675

[30]   Hu, D., Zheng, H., Liu, H., Li, M., Ren, W., Liao, W., et al. (2008) Immunoglobulin expression and its biological significance in cancer cells. Cellular and Molecular Immunology, 5, 319-324. doi:10.1038/cmi.2008.39

[31]   Chen, Z., Qiu, X. and Gu, J. (2009) Immunoglobulin expression in non-lymphoid lineage and neoplastic cells. American Journal of Pathology, 174, 1139-1148. doi:10.2353/ajpath.2009.080879

[32]   Lee, G. (2012) Cancerous immunoglobulins and CA215: Implications in cancer immunology. American Journal of Immunology, 8, 101-116. http://0.3844/ajisp.2012.101.116

[33]   Chen, Z., Huang, X., Ye, J., Pan, P., Cao, Q., Yang, B., et al. (2010) Immunoglobulin G is present in a wide variety of soft tissue tumors and correlates well with proliferation markers and tumor grades. Cancer, 116, 1953-1963. doi:10.1002/cncr.24892

[34]   Liu, Y., Chen, Z., Niu, N., Chang, Q., Deng, R., Korteweg, C., et al. (2012) IgG gene expression and its possible significance in prostate cancers. The Prostate, 72, 690-701. doi:10.1002/pros.21476

[35]   Niu, N., Zhang, J., Guo, Y., Zhao, Y., Korteweg, C. and Gu, J. (2011) Expression and distribution of immunoglobulin G and its receptors in the human nervous system. International Journal of Biochemistry and Cell Biology, 43, 556-563. doi:10.1016/j.biocel.2010.12.012

[36]   Niu, N., Zhang, J., Huang, T., Sun, Y., Chen, Z., Yi, W., et al. (2012) IgG expression in human colorectal cancer and its relationship to cancer cell behaviors. PLoS One, 7, e47362. doi:10.1371%2Fjournal.pone.0047362

[37]   Niu, N., Zhang, J., Wang, S., Sun, Y., Korteweg, C., Gao, W., et al. (2011) Expression and distribution of immunoglobulin G and its receptors in an immune privileged site: The eye. Cellular and Molecular Life Sciences, 68, 2481-2492. doi:10.1007/s00018-010-0572-7

[38]   Qiu, Y., Korteweg, C., Chen, Z., Li, J., Luo, J., Huang, G., et al. (2012) Immunoglobulin G expression and its colocalization with complement proteins in papillary thyroid cancer. Modern Pathology, 25, 36-45. doi:10.1038/modpathol.2011.139

[39]   Zhao, Y., Liu, Y., Chen, Z., Korteweg, C. and Gu, J. (2011) Immunoglobulin G (IgG) expression in human umbilical cord endothelial cells. Journal of Histochemistry and Cytochemistry, 59, 474-488.

[40]   Zhu, X., Wu, L., Zhang, L., Hao, P., Zhang, S., Huang, J., et al. (2010) Distinct regulatory mechanism of immunoglobulin gene transcription in epithelial cancer cells. Cellular Molecular Immunology, 7, 279-286. doi:10.1038/cmi.2010.13

[41]   Muramatsu, M., Kinoshita, K., Fagarasan, S., Yamada, S., Shinkai, Y. and Honjo, T. (2000) Class switch recombinetion and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell, 102, 553-563. doi:10.1016/S0092-8674(00)00078-7

[42]   Papavasiliou, F.N. and Schatz, D.G. (2002) Somatic hypermutation of immunoglobulin genes: Merging mechanisms for genetic diversity. Cell, 109, S35-S44. doi:10.1016/S0092-8674(02)00706-7

[43]   Honjo, T., Kinoshita, K. and Muramatsu M. (2002) Molecular mechanism of class switch recombination: Linkage with somatic hypermutation. Annual Review of Immunology, 20, 165-196. doi:10.1146/annurev.immunol.20.090501.112049

[44]   Lee, G., Cheung, A.P., Li, B., Ge, B. and Chow, P.-M. (2012) Molecular and immuno-characteristics of immunoglobulin-like glycoproteins in cancer cell-expressed biomarker, CA215. Immunological Investigations, 41, 429-446. doi:10.3109/08820139.2012.661007

[45]   Chu, P.G. and Weiss, L.M. (2002) Expression of cytokeratin 5/6 in epithelial neoplasms: An immunohisto- chemical study of 509 cases. Modern Pathology, 15, 6-10. doi:10.1038/modpathol.3880483

[46]   Lee, G., Zhu, M. and Ge, B. (2012) Potential monoclonal antibody therapy for the treatment of ovarian cancer. In: Farghaly, S.A., Ed., Ovarian Cancer-Basic Science Perspective, InTech, Vancouver, 385-406. doi:10.5772/27471

[47]   Lee, G. and Ge, B. (2010) Inhibition of in vitro tumor cell growth by RP215 monoclonal antibody and antibodies raised against its anti-idiotype antibodies. Cancer Immunology, Immunotherapy, 59, 1347-1356. doi:10.1007/s00262-010-0864-7

[48]   Koropatnick, T.A., Engle, J.T., Apicella, M.A., Stabb, E.V., Goldman, W.E. and McFall-Ngai, M.J. (2004) Microbial factor-mediated development in a host-bacterial mutualism. Science, 306, 1186-1188. doi:10.1126/science.1102218

[49]   O’Neill, L.A.J. (2008) Toll-like receptors in cancer. Oncogene, 27, 158-160. doi:10.1038/sj.onc.1210903

[50]   O’Neill, L.A., Bryant, C.E. and Doyle, S.L. (2009) Therapeutic targeting of toll-like receptors for infectious and inflammatory diseases and cancer. Pharmacological Reviews, 61, 177-197. doi:10.1124/pr.109.001073

[51]   Rakoff-Nahoum, S. and Medzhitov, R. (2009) Toll-like receptors and cancer. Nature Reviews. Cancer, 9, 57-63.

[52]   Cook, D.N., Pisetsky, D.S. and Schwartz, D.A. (2004) Toll-like receptors in the pathogenesis of human disease. Nature Immunology, 5, 975-979.

[53]   Morikawa, T., Sugiyama, A., Kume, H., Ota, S., Kashima, T., Tomita, K., et al. (2007) Identification of toll-like receptor 3 as a potential therapeutic target in clear cell renal cell carcinoma. Clinical Cancer Research, 13, 5703-5709. doi:10.1158/1078-0432.CCR-07-0603

[54]   Salaun, B., Lebecque, S., Matikainen, S., Rimoldi, D. and Romero, P. (2007) Toll-like receptor 3 expressed by melanoma cells as a target for therapy? Clinical Cancer Research, 13, 4565-4574. doi:10.1158/1078-0432.CCR-07-0274

[55]   Yang, H., Zhou, H., Feng, P., Zhou, X., Wen, H., Xie, X., et al. (2010) Reduced expression of toll-like receptor 4 inhibits human breast cancer cells proliferation and inflammatory cytokines secretion. Journal of Experimental and Clinical Cancer Research, 29, 92. doi:10.1186/1756-9966-29-92

[56]   Droemann, D., Albrecht, D., Gerdes, J., Ulmer, A.J., Branscheid, D., Vollmer, E., et al. (2005) Human lung cancer cells express functionally active toll-like receptor 9. Respiratory Research, 6, 1. doi:10.1186/1465-9921-6-1

[57]   Ilvesaro, J.M., Merrell, M.A., Swain, T.M., Davidson, J., Zayzafoon, M., Harris, K.W., et al. (2007) Toll like receptor-9 agonists stimulate prostate cancer invasion in vitro. Prostate, 67, 774-781. doi:10.1002/pros.20562

[58]   Merrell, M.A., Ilvesaro, J.M., Lehtonen, N., Sorsa, T., Gehrs, B., Rosenthal, E., et al. (2006) Toll-like receptor 9 agonists promote cellular invasion by increasing matrix metalloproteinase activity. Molecular Cancer Research, 4, 437-447. doi:10.1158/1541-7786.MCR-06-0007

[59]   Salaun, B., Coste, I., Rissoan, M.C., Lebecque, S.J. and Renno, T. (2006) TLR3 can directly trigger apoptosis in human cancer cells. Journal of Immunology, 176, 4894- 4901.

[60]   O’Sullivan, T., Saddawi-Konefka, R., Vermi, W., Koebel, C.M., Arthur, C., White, J.M., et al. (2012) Cancer immunoediting by the innate immune system in the absence of adaptive immunity. The Journal of Experimental Medicine, 209, 1869-1882. doi:10.1084%2Fjem.20112738

[61]   Sato, Y., Goto, Y., Narita, N. and Hoon, D.S. (2009) Cancer cells expressing toll-like receptors and the tumor microenvironment. Cancer Microenvironment, 2, 205-214. doi:10.1007%2Fs12307-009-0022-y

[62]   Lee, J.W., Choi, J.J., Seo, E.S., Kim, M.J., Kim, W.Y., Choi, C.H., et al. (2007) Increased toll-like receptor 9 expression in cervical neoplasia. Molecular Carcinogenesis, 46, 941-947.

[63]   Kelly, M.G., Alvero, A.B., Chen, R., Silasi, D.-A., Abrahams, V.M., Chan, S., et al. (2006) TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Research, 66, 3859-3868. doi:10.1158/0008-5472.CAN-05-3948

[64]   Nishimura, M. and Naito, S. (2005) Tissue-specific mRNA expression profiles of human toll-like receptors and related genes. Biological and Pharmaceutical Bulletin, 28, 886-892. doi:10.1248/bpb.28.886

[65]   Kim, W.Y., Lee, J.W., Choi, J.J., Choi, C.H., Kim, T.J., Kim, B.G., et al. (2008) Increased expression of toll-like receptor 5 during progression of cervical neoplasia. International Journal of Gynecological Cancer, 18, 300- 305. doi:10.1111/j.1525-1438.2007.01008.x

[66]   Huang, B., Zhao, J., Li, H., He, K.L., Chen, Y., Chen, S.H., et al. (2005) Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Research, 65, 5009-5014. doi:10.1158/0008-5472.CAN-05-0784

[67]   Zhou, M., McFarland-Mancini, M.M., Funk, H.M., Husseinzadeh, N., Mounajjed, T. and Drew, A.F. (2009) Toll-like receptor expression in normal ovary and ovarian tumors. Cancer Immunology, Immunotherapy, 58, 1375- 1385. doi:10.1007/s00262-008-0650-y

[68]   Li, Q., Withoff, S. and Verma, I.M. (2005) Inflammation-associated cancer: NF-kappaB is the lynchpin. Trends in Immunology, 26, 318-325. doi:10.1016/

[69]   Griffin, J.D. (2001) Leukemia stem cells and constitutive activation of NF-kappaB. Blood, 98, 2291. doi:10.1182/blood.V98.8.2291a

[70]   Xie, W., Wang, Y., Huang, Y., Yang, H., Wang, J. and Hu, Z. (2009) Toll-like receptor 2 mediates invasion via activating NF-kappaB in MDA-MB-231 breast cancer cells. Biochemical and Biophysical Research Communications, 379, 1027-1032. doi:10.1016/j.bbrc.2009.01.009

[71]   Pikarsky, E., Porat, R.M., Stein, I., Abramovitch, R., Amit, S., Kasem, S., et al. (2004) NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature, 431, 461-466.

[72]   So, E.Y. and Ouchi, T. (2010) The application of toll like receptors for cancer therapy. International Journal of Biological Sciences, 6, 675-681. doi:10.7150/ijbs.6.675

[73]   Vesely, M.D., Kershaw, M.H., Schreiber, R.D. and Smyth, M.J. (2011) Natural innate and adaptive immunity to cancer. Annual Review of Immunology, 29, 235-271. doi:10.1146/annurev-immunol-031210-101324

[74]   Schmausser, B., Andrulis, M., Endrich, S., Muller-Hermelink, H.K. and Eck, M. (2005) Toll-like receptors TLR4, TLR5 and TLR9 on gastric carcinoma cells: An implication for interaction with Helicobacter pylori. International Journal of Medical Microbiology, 295, 179- 185. doi:10.1016/j.ijmm.2005.02.009

[75]   Furrie, E., Macfarlane, S., Thomson, G. and Macfarlane, G.T. (2005) Toll-like receptors-2, -3 and -4 expression patterns on human colon and their regulation by mucosal-associated bacteria. Immunology, 115, 565-574. doi:10.1111%2Fj.1365-2567.2005.02200.x

[76]   Huang, B., Zhao, J., Unkeless, J.C., Feng, Z.H. and Xiong, H. (2008) TLR signaling by tumor and immune cells: A double-edged sword. Oncogene, 27, 218-224. doi:10.1038/sj.onc.1210904

[77]   O’Neill, L.A. (2004) TLRs: Professor Mechnikov, sit on your hat. Trends in Immunology, 25, 687-693. doi:10.1016/